Dana-Farber Scientists Reveal How Follicular Lymphoma Transitions to More Aggressive Disease
The research could help lead to novel approaches to monitoring or early intervention.
Erin Parry, MD, PhD, cares for patients with follicular lymphoma, a form of blood cancer that affects immune cells called B cells in the lymph nodes. It is considered “indolent,” meaning it grows very slowly and often does not require treatment. In about 10 to 25 percent of patients, however, the disease transforms into an aggressive type of lymphoma that requires immediate intervention.
A lymph node in transition from indolent follicular lymphoma (top), which maintains some of its structure, to aggressive large B-cell lymphoma (bottom right), which has lost its structure.
Exactly how this transformation occurs is unclear. To learn more, Parry, a physician-scientist in the Lymphoma Program at Dana-Farber, embarked on a study that could help improve care for patients.
The research, published in Cancer Discovery, uncovered key changes in unexpected cell types in lymph nodes upon the transition to aggressive large B cell lymphoma. The findings could help investigators find ways to detect the transition earlier, possibly even non-invasively, and to improve treatments for patients.
“We know our patients fear this transition,” says Parry. “It was really important for us to try to learn more so we can improve detection and future therapies for our patients.”
An inventory of cells
The team – led by three senior scientists including Parry, Gad Getz, PhD, at the Broad Institute, and Sizun Jiang, PhD, at Beth Israel Deaconess Medical Center – began by looking at tissue samples from lymph nodes of patients with lymphoma that had been banked at Dana-Farber for research. The tissues were preserved in a way that enabled a broad range of cells to be captured and studied.
The team knew that lymph nodes contain B cells that monitor the body for signs of pathogens and respond with an antibody defense. In lymphoma, these B cells become malignant.
But researchers knew little about which other cells and genes might be involved in the transformation. To learn more, the team, including first authors Laura Beckmann, MD, a post-doc in Parry’s lab, Nick Haradhvala, PhD, a group leader in the Getz lab, and Stephanie Yiu, PhD, a post-doc in the Jiang lab, analyzed the cells using RNA sequencing to determine which genes were expressed in the tissues. This data provides clues about what the types of cells are present and how they function.
The team found that cancerous B cells were not changing as much as the disease transitioned, but the surrounding cells were. Cells called stromal cells, which help create structure in the lymph node, and immune cells called macrophages, which normally have an anti-cancer effect, were changing dramatically.
“When we saw that there were these important cell types that were profoundly different between indolent samples and samples of disease that had transformed to an aggressive cancer, we wanted to study them in more depth and also see them spatially,” says Parry.
Organizational Changes
To see changes in a tissue sample spatially, such as on a slide, you need to know what to look for. For example, pathologists use special stains on a slide to track B cells and other cells to diagnose lymphoma.
Under the microscope, a healthy lymph node sample contains oval compartments that contain diverse collections of B cells, known as follicules. When indolent follicular lymphoma develops, the compartments expand and the B cells inside become dominated by identical cancerous B cells.
“While follicular lymphoma is still a malignancy, it retains some of that normal structure and you can see expanded B cell follicules, which appear as these roundish objects throughout,” says Parry.
To see the transformation to aggressive lymphoma on a slide, the team used their RNA expression data to track the unexpected cell types that they found were relevant to the transition of the disease. What they saw helped them understand the transformation even more deeply.
The slides revealed that, during the transition, the oval compartments in lymph nodes break down. The lymph nodes transform from organized but faulty to disordered and nonfunctional.
Specifically, stromal cells disappear and are replaced by fibroblastic cells, similar to those typically seen in solid tumors. This shift contributes to the loss of structure. In addition, cells called macrophages lose their anti-cancer functions and collect alongside the fibroblastic cells, altering the structure and the communications between cells.
“We lose that nodal structure completely,” says Parry. “This work required a lot of close collaboration across our labs. I don’t think this type of study would have been possible with a single lab trying to do it alone.”
Next steps
The team is now trying to determine how this new information can help improve treatment and care for patients. One challenge for patients is that monitoring them for signs of malignant transition requires repeated biopsies.
In this study, however, the researchers found evidence that the transition might be detectable in blood samples. For example, fragments of cells that are present and visible in blood samples before the transition disappear from blood as the transition progresses.
“We actually could see these transition-related soluble signals in the blood, which was very exciting,” says Parry. “There could be a way to monitor patients for signs of transition non-invasively, though more testing is needed.”
Parry is also interested in learning more about what is driving the transition. A deeper understanding could point to new targets for therapies, ways to improve immunotherapies for patients, or ways to identify patients at a high-risk of transition.
“We would love to reassure our patients and have a treatment strategy designed for early intervention or prevention of adverse transformations,” says Parry.
Written by: Beth Dougherty
Medically Reviewed By: Erin Parry, MD, PhD
